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 In the UK, there are over 80,000 admissions annually with 
acute coronary syndromes (ACS). Management of ST-elevation 
myocardial infarction (STEMI) involves primary percutaneous 
coronary intervention (PCI), which is delivered via dedicated 
heart attack centres. Non-ST elevation-ACS (NSTE-ACS) 
accounts for two-thirds of ACS presentations, affecting an older 
cohort of patients – often with more complex comorbidities. 
Initial management is with anti-thrombotic therapy with 
a view to PCI within 24 hours for the most acute cases and 
within 72 hours for all others. However, varying management 
pathways and access to specialist cardiology services results 
in variable times to deﬁnitive treatment. Advances in the 
sensitivity of cardiac biomarkers and the use of risk assessment 
tools now enable rapid diagnosis within a few hours of 
symptom onset. Advances in invasive management and drug 
therapy have resulted in improved clinical outcomes with 
resultant decline in mortality associated with ACS. 
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 Introduction 
 Coronary artery disease (CAD) remains the leading cause 
of death worldwide. 1 Clinical manifestations include stable 
angina, acute coronary syndromes (ACS), heart failure and 
sudden death. The term ACS encompasses ST-elevation 
myocardial infarction (STEMI) and non-ST elevation ACS 
(NSTE-ACS), which encompasses non-ST elevation myocardial 
infarction (NSTEMI) and unstable angina (UA). Approximately 
two thirds of ACS presentations are with NSTE-ACS and the 
remainder are STEMI. 2,3 Furthermore, with the advent of high 
sensitivity troponin assays, many patients previously classified 
as UA are now being diagnosed with NSTEMI. This has resulted 
in the incidence of UA to fall while NSTEMI is on the rise. 3 
While the age- and sex-adjusted incidence of ACS is falling, 
there remains an associated mortality risk with the condition. 2 
In the UK, there are over 80,000 hospital admissions with ACS 
annually. 3 Those presenting with STEMI tend to be younger 
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(average age 65 years) compared with patients with NSTE-ACS 
(average age 71 years), 3 who also frequently have multi-vessel 
coronary disease and more complex comorbidities. In the UK, 
the 30-day mortality associated with STEMI is 8.1%. 3 1-year 
mortality is higher for patients presenting with NSTE-ACS 
compared with STEMI (14.3% versus 9.5%) reflecting the fact 
that while patients presenting with NSTE-ACS appear more 
stable at presentation, their long-term outcome is worse. 4,5 
 The standard of care for patients presenting with ACS includes 
early coronary angiography with a view to revascularisation 
with percutaneous coronary intervention (PCI) or coronary 
artery bypass surgery (CABG). Patients with STEMI typically 
present acutely with severe ongoing cardiac chest pain and ST 
elevation on 12-lead electrocardiogram (ECG) (Fig  1 ). In the 
UK, there is an established STEMI pathway, whereby patients 
are taken by the ambulance service directly to a heart attack 
centre where they receive immediate PCI (Fig  2 ). Patients with 
NSTE-ACS usually present more insidiously and are commonly 
seen in the local emergency department. This may not be a 
PCI-capable centre and patients are frequently admitted under 
the general medical team rather than directly under cardiology. 
This may introduce delays in care before the patient receives 
definitive treatment. 
 Universal deﬁnition of myocardial infarction 
 In 2012, the third universal definition of myocardial infarction 
was published. 6 This update reflects the increasing sensitivity 
of biochemical assays and the additional use of imaging 
modalities to diagnose myocardial infarction. The term 
myocardial infarction should be used when there is evidence of 
myocardial necrosis in a clinical setting consistent with acute 
myocardial ischaemia. There should be a rise and/or fall of 
cardiac biomarker value (preferably cardiac troponin) with at 
least one of the following: 
 >  symptoms of ischaemia 
 >  new or presumed new signifi cant ST segment or T wave 
changes, or new left bundle branch block 
 >  development of pathological Q waves on ECG 
 >  imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality 
 >  identifi cation of intracoronary thrombus on angiography or 
autopsy. 
 Furthermore, myocardial infarction can be further classified 
into five subtypes according to underlying aetiology (Box  1 ). In 
clinical practice, type 1 (spontaneous myocardial infarction), 
CMJv16n6S-Rakhit.indd   43 23/11/16   9:41 AM
Tushar Kotecha and Roby D Rakhit
s44 © Royal College of Physicians 2016. All rights reserved.
and type 2 (secondary to ischaemic imbalance) are the 
most commonly encountered. The use of imaging, such as 
echocardiography or cardiovascular magnetic resonance, 
can be useful to differentiate the two as type 2 is not usually 
associated with loss of viable myocardium or regional wall 
motion abnormality. 
 The term ACS encompasses a clinical spectrum of 
pathophysiology and presentations of symptomatic coronary 
disease. This is usually due to atherosclerotic plaque rupture, 
ulceration or erosion that results in intraluminal thrombus 
formation and compromises myocardial blood flow leading to 
myocardial necrosis and release of cardiac enzymes. Usually, 
STEMI is a manifestation of complete vessel occlusion due to 
acute thrombus formation secondary to a ruptured plaque. If 
left untreated, this results in transmural infarction and extensive 
myocardial necrosis. Characteristically, the 12-lead ECG shows 
ST-segment elevation localised to an epicardial vessel territory. 
In contrast, NSTE-ACS results from incomplete or transient 
vessel occlusion. The 12-lead ECG may show ST segment 
depression, T wave inversion, or be completely normal (Fig  3 ). 
NSTEMI is associated with release of cardiac enzymes such as 
troponin signifying a degree of myocardial necrosis, whereas 
UA has no enzyme release but the presence of worsening or 
crescendo symptoms. This differentiation of subtypes of ACS 
is often used clinically as it allows for diversion of patients to 
different treatment pathways according to clinical urgency. 
 Non-ST elevation acute coronary syndrome 
 NSTE-ACS may precede STEMI or sudden cardiac death. 
Despite often relatively short-lived symptoms that respond to 
medical therapy with nitrates and opioids, the risk of death 
or STEMI in the first 30 days is up to 10%. 7 Up to half of 
patients will experience recurrent ischaemia despite initiation 
of medical therapy. 8,9 The main determinants of prognosis are 
extent of myocardial injury, extent of coronary artery disease 
and instability of disease. 
 Initial assessment of patients with suspected NSTE-ACS is 
often performed by emergency department or general medical 
physicians. It is important that patients at high risk or those 
with ongoing ischaemia receive urgent cardiology review and 
definitive treatment with coronary angiography and PCI (Fig  4 ). 
 Diagnosis is made from a combination of clinical history, ECG 
changes and cardiac troponin release. Troponin is a component 
of the myocardial contractile apparatus that is released from 
damaged myocytes. It is not detectable in healthy subjects. 
There are a number of commercially available assays, most of 
which test for troponin T or troponin I. Normal ranges can 
vary signifi cantly between assays. Furthermore, some manufac-
turers also quote different cut-off values for males and females. 
A number of studies have demonstrated that elevated troponin 
is associated with increased risk of mortality. 7,10 More recently, 
high sensitivity troponin assays have become available, allow-
ing for early diagnosis and ‘early rule out’ of NSTEMI within 
3 hours of onset of chest pain when used appropriately. 11,12 
 Fig 1.  Example of 12-lead 
electrocardiogram showing 
ST-segment elevation in the 
inferior leads (II, III and aVF) 
with reciprocal ST-segment 
depression in leads V1–V4, 
I and aVL. 
 Fig 2.  Coronary angiogram of patient presenting with inferior ST-
elevation myocardial infarction. A – occluded right coronary artery (arrow); 
B – successful restoration ﬂ ow  following implantation of a drug-eluted stent. 
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 While there is often a reliance on cardiac troponin, it is 
important to remember that a number of patients may have 
unstable coronary disease without troponin release. It is 
therefore important that the result is put into clinical context. 
Additionally, troponin may be falsely elevated in conditions 
such as renal failure, pulmonary embolism, myocarditis and 
heart failure. Serial testing at presentation then again after 
3 hours is now incorporated in many guidelines. Dynamic 
rise in troponin (with or without signs and symptoms of 
myocardial ischaemia) is consistent with a diagnosis of 
myocardial infarction, whereas no change (even if elevated 
above upper limit of normal) should prompt investigation for 
alternative diagnoses. 13 For high sensitivity troponin assays, 
a fivefold increase has greater than 90% positive predictive 
value for detection of myocardial infarction, whereas a three 
fold increase has a positive predictive value of only 50–60%. 14 
The next generation of troponin assays have the potential 
to diagnose myocardial infarction within 1 hour and are 
already in use in some centres. 15 These are commonly used 
in conjunction with risk scores and, as long as the sample is 
collected more than 2 hours after onset of symptoms, may allow 
for rapid discharge of patients without ACS. 
 Box 1. Subtypes of myocardial infarction 6 
 > Type 1: spontaneous myocardial infarction 
  Related to atherosclerotic plaque rupture, ulceration, fissuring, erosion or dissection with resultant intraluminal thrombus leading to 
decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. 
 >  Type 2: myocardial infarction secondary to ischaemic imbalance 
  Myocardial injury with necrosis where a condition other than CAD contributes to imbalance between myocardial oxygen supply and/
or demand, eg coronary endothelial dysfunction, coronary artery spasm, coronary embolus, arrhythmia, anaemia, respiratory failure, 
hypotension, hypertension. 
 >  Type 3: myocardial infarction resulting in death when biomarker values are unavailable 
  Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new left bundle branch 
block (LBBB), but death occurring before blood samples could be obtained or before cardiac biomarker could rise. 
 > Type 4a: myocardial infarction related to PCI 
  Defined as elevation of troponin more than five times the 99th percentile of upper reference level in patients with normal baseline values, or a 
rise in troponin greater than 20% of baseline value. In addition, either (i) symptoms suggestive of myocardial ischaemia, (ii) new ischaemic ECG 
changes, (iii) angiographic loss of patency of major coronary artery or side branch or reduced flow, or (iv) imaging evidence of new regional wall 
motion abnormality of loss of viable myocardium. 
 > Type 4b: myocardial infarction related to stent thrombosis 
  Stent thrombosis on angiography or autopsy with an associated rise and/or fall in cardiac biomarker values. 
 > Type 5: myocardial infarction related to CABG 
  Elevation in cardiac biomarkers values more than 10 times with 99th percentile of upper reference level in patients with normal baseline 
values. In addition, either (i) new pathological Q waves or LBBB, (ii) angiographic evidence of new graft or native coronary artery 
occlusion, or (iii) imaging evidence of new regional wall motion abnormality of loss of viable myocardium.
 CABG = coronary artery bypass surgery; CAD = coronary artery disease; ECG = electrocardiogram; PCI = percutaneous coronary intervention 
 Fig 3.  Example of 12-lead 
electrocardiogram showing 
antero-lateral T wave inversion 
(leads V2–V6, I and aVL) 
consistent with non-ST 
elevation-acute coronary 
syndrome. 
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arrhythmia or haemodynamic instability, an early invasive 
strategy (within 24 hours) for those with a GRACE score greater 
than 140, and coronary angiography within 72 hours for those 
with low to intermediate risk. 13  
 Contemporary UK data suggest there is room for 
improvement in timely access to coronary angiography. In 
2014, only 54% of patients presenting with NSTEMI underwent 
coronary angiography within 72 hours and 67% within 
96 hours. 3 These figures are likely to be as a consequence of 
many patients being admitted to hospitals without coronary 
intervention facilities and with lack of access to early cardiology 
specialist input. Centres have introduced novel pathways to 
expedite access to coronary angiography. Examples include 
 > direct referral of selected patients from the emergency depart-
ment in district general hospitals to the cardiology team at the 
closest heart attack centre with a 24-hour PCI service 
 > direct access for the ambulance service to the heart attack 
centre for patients with high-risk NSTE-ACS. 19 
 ST-elevation myocardial infarction 
 Primary PCI is now established as the optimal revascularisation 
method for STEMI in the UK. This is as a result of data showing 
improved mortality, non-fatal myocardial infarction and stroke 
compared with fibrinolysis. 20 This is based on the ability to 
deliver primary PCI in a timely manner. Where primary PCI 
cannot be reliably delivered within 120 minutes, fibrinolysis may 
still be considered as an option. Heart attack centres have been 
set up to rapidly mobilise staff and deliver immediate treatment 
 Fig 4.  Coronary angiogram of a patient presenting with non-ST 
elevation-acute coronary syndrome. Electrocardiogram showed anterior 
T wave inversion. A – critical stenosis in proximal left anterior descending 
artery (arrow); B – successful restoration of ﬂ ow following implantation of a 
drug-eluted stent. 
Box 3. Recommendations for timing of coronary 
angiography NSTE-ACS according to clinical risk
 Very high risk: coronary angiography recommended in <2 hours 
 > mechanical complications of MI 
 > dynamic ST/T changes 
 > acute HF 
 High risk: coronary angiography recommended in <24 hours 
 > positive troponin 
 > dynamic ST/T changes 
 > GRACE score>140 
 Intermediate risk: coronary angiography recommended <72 hours 
 > Diabetes 
 > CKD (eGFR<60) 
 > EF<40% or congestive HF 
 > prior PCI or CABG 
 > early post MI angina 
 > GRACE score>109 and <140 
 Low risk 
 > Any characteristics not mentioned above 
 CABG = coronary artery bypass surgery; CKD = chronic kidney disease; 
ECG = electrocardiogram; EF = ejection fraction; eGFR = estimated glomerular 
filtration rate; GRACE = Global Registry of Acute Coronary Events; HF = heart 
failure; MI = myocardial infarction; NSTE-ACS = Non-ST elevation-acute 
coronary syndrome; PCI = percutaneous coronary intervention 
 A number of risk scoring systems have been developed 
to highlight those at highest risk and in need of urgent 
intervention. The two most commonly used are GRACE 
(Global Registry of Acute Coronary Events) and TIMI 
(Thrombolysis in Myocardial Infarction). GRACE is based 
on a multinational registry of over 70,000 patients admitted 
with ACS. 16 The primary endpoint was all-cause mortality at 
6 months. From this, nine predictors of mortality were derived 
(Box  2 ). Points are allocated to each of the predictors to give an 
overall score, which correlates to an in-hospital and 6-month 
mortality risk. A GRACE score above 140 is defined as high risk 
and associated with more than 2.8% risk of in-hospital death. 16 
An early invasive strategy with coronary angiography within 
24 hours has been shown to be better than a delayed strategy 
(more than 36 hours) for patients within this group. 17 
 Current UK and European guidelines recommend inpatient 
coronary angiography for patients presenting with NSTE-
ACS. Timing is based on assessment of risk (Box  3 ). National 
Institute for Health and Care Excellence (NICE) guidelines 
recommend urgent coronary angiography within 24 hours for 
patients who are clinically unstable, for example those with 
ongoing chest pain, and within 72 hours for all other patients. 18 
European Society of Cardiology guidelines recommend 
urgent coronary angiography within 2 hours for patients 
with refractory angina, associated heart failure, ventricular 
 Box 2. Predictors of 6-month mortality following ACS 16 
 > Age per 10-year increase above 40 years 
 > History of previous myocardial infarction 
 > Heart failure 
 > Tachycardia 
 > Hypotension 
 > Elevated serum creatinine 
 > Elevated cardiac enzymes 
 > ST-segment deviation on ECG 
 > Absence of in-hospital PCI 
 ACS = acute coronary syndrome; ECG = electrocardiogram; PCI = percutaneous 
coronary intervention 
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upon arrival of the patient. Every minute treatment is delayed 
results in myocardial damage and consequent increased risk of 
mortality. A door-to-balloon time of 30 minutes is associated 
with 3% in-hospital mortality compared with 6% mortality at 
120 minutes and 9% at 180 minutes. 21 In the UK, more than 
90% of patients receive primary PCI within 90 minutes of 
admission to a heart attack centre. 3 Door-to-balloon (and call-
to-balloon) times can be reduced by ambulance crews delivering 
patients directly to the cardiac catheterisation laboratory rather 
than admitting via the emergency department. 22 
 The majority of routine and primary PCI in the UK is now 
undertaken via the radial rather than femoral route. This has 
been shown to reduce mortality and complications such as 
major bleeding. 23,24 It also allows for early mobilisation and 
discharge, and is generally preferred by patients. 
 Antiplatelet therapy 
 A key pathological feature of acute coronary syndrome is platelet 
activation, which results in thrombin generation, activation of 
the coagulation cascade and release of inflammatory mediators. 25 
Anti-thrombotic pharmacotherapy is therefore an important 
adjunct to PCI and an integral part of secondary prevention. 
 The mainstay of acute and long-term management includes 
aspirin and a P2Y 12 inhibitor, such as clopidogrel or ticagrelor. 
Clopidogrel is a thienopyridine drug that results in irreversible 
platelet inhibition. It is a pro-drug with an onset of action of 
2–4 hours and duration of effect of up to 10 days. Ticagrelor is a 
new P2Y 12 inhibitor that does not require metabolism to an active 
metabolite. It causes reversible platelet inhibition and has a rapid 
onset of action (approximately 30 minutes). This is theoretically 
advantageous in the acute phase where rapid platelet inhibition 
is required. The duration of effect is 3–4 days. The CURE 
(Clopidogrel in Unstable angina to prevent Recurrent Events) 
study initially showed benefit for clopidogrel in addition to 
aspirin in reducing cardiovascular death, myocardial infarction 
and stroke for patients with ACS. 26 More recently, the PLATO 
(PLATelet inhibition and patient Outcomes) study showed 
benefit for ticagrelor over clopidogrel for the same endpoints 
without a significant increase in major bleeding. 27 However, there 
was an increase in non-major bleeding with ticagrelor. Cangrelor 
is a new intravenous reversible antiplatelet agent. It has a rapid 
onset within a few minutes and duration of effect of 1–2 hours. 
While not currently used in routine practice in the UK, it has 
shown potential in the acute phase of STEMI where rapid platelet 
inhibition is required. 28 
 Current guidelines recommend dual antiplatelet therapy 
for 1 year following ACS. 13 This was partly based on the risk 
of stent thrombosis with early generation drug eluting stents. 
However, there is now a move towards tailored antiplatelet 
therapy according to the clinical need and bleeding risk of 
the individual patient. The recent DAPT (Dual Antiplatelet 
Therapy) study showed that dual antiplatelet therapy beyond 
1 year (compared with aspirin alone) after implantation 
of a drug eluting stent significantly reduced the risk of 
stent thrombosis and major adverse cardiovascular and 
cerebrovascular events but with an associated increase in risk of 
bleeding. 29 This bleeding risk is highest in older patients, those 
with existing coagulation defects and those with comorbidities, 
including liver and renal failure. With the introduction of 
new generation drug eluting stents, there is emerging evidence 
for the safety of shortening dual antiplatelet therapy to as 
little as 1 month. 30 Therefore, selected patients with high 
cardiovascular risk or recurrent events may benefit from 
prolonged antiplatelet therapy beyond 1 year whereas those 
with lower cardiovascular risk and/or high bleeding risk may be 
treated with a shorter course of dual antiplatelet therapy. 
 Anticoagulant therapy 
 In addition to antiplatelet therapy, low molecular weight 
heparins are recommended in the acute phase of NSTE-
ACS prior to angiography. Commonly used agents include 
enoxaparin, dalteparin and tinzaparin. The factor Xa inhibitor 
fondaparinux is now preferred in many centres as it has been 
shown to be non-inferior to enoxaparin with 50% reduced 
bleeding risk. 31 Anticoagulation is not routinely prescribed 
long term following ACS. However, there is evidence that 
novel anticoagulants (NOAC), such as rivaroxaban, improve 
outcomes following ACS; this is at the expense of increased 
bleeding. 32 NICE currently recommends the addition of 
rivaroxaban in selected high-risk patients. 33 
 A subset of patients presenting with ACS may have another 
indication for long-term anticoagulation, such as atrial 
fibrillation. Triple therapy with aspirin, clopidogrel and 
warfarin (or NOAC) is associated with a significantly increased 
bleeding risk compared with dual antiplatelet therapy. 34 
However, effective platelet inhibition is essential in the early 
phase following PCI to reduce the risk of early stent thrombosis. 
It is therefore suggested that patients with low bleeding risk are 
treated with triple therapy for 6 months following PCI, followed 
by dual therapy with warfarin (or NOAC) plus aspirin or 
clopidogrel for another 6 months. 13 Patients with high bleeding 
risk should be treated with triple therapy for 1 month, followed 
by warfarin (or NOAC) plus aspirin or clopidogrel for the 
remainder of the year. 13 After 1 year, treatment with warfarin 
(or NOAC) alone is recommended. 
 Conclusions 
 ACS is a common presentation to acute services. There is 
a clearly defined treatment pathway for STEMI with direct 
admission to heart attack centres with a view to emergency 
PCI. NSTE-ACS is a more common presentation of ACS, 
affecting an older cohort of patients – often with more complex 
comorbidities. Management pathways vary, resulting in 
variable times to cardiology review and definitive treatment. 
Initial management is with anti-thrombotic therapy with a 
view to PCI in a timely manner. Advances in the sensitivity of 
cardiac biomarkers and risk assessment tools now enable rapid 
diagnosis within a few hours of symptoms onset. Advances 
in invasive management and drug therapy have resulted in 
improved short-term and long-term clinical outcomes. ■ 
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